Inhibitor

(redirected from Direct thrombin inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Wikipedia.

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
References in periodicals archive ?
Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.
Direct thrombin inhibitors (DTIs) DTI Administration Indications Laboratory monitoring Argatroban IV, 2 mg/kg/min Substitute for PTT 1.
The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
To what extent do new anticoagulants, such as direct thrombin inhibitors, affect standard coagulation tests?
Pradaxa, an oral direct thrombin inhibitor that was discovered and developed by Boehringer Ingelheim, is the first new oral anticoagulant approved in USA in more than 50 years.
Liver function abnormalities, which caused the only previously available oral direct thrombin inhibitor, ximelagatran, to be denied FDA approval, were infrequent in both groups.
Antman disclosed no relationship with Boehringer Ingelheim, but has relationships with several other drug companies, including a company developing a rival direct thrombin inhibitor.
Additional investigations ruled out a coexisting common pathway defect (factor V 144%, factor X 86%, factor II not done), fibrinogen deficiency (fibrinogen, 3700 mg/L, reference interval 1800-4000 mg/L), a direct thrombin inhibitor (thrombin time, 18.
More recently, the direct thrombin inhibitor ximelagatran was found to have a benefit similar to that of warfarin but with an unacceptable incidence of hepatotoxicity.
Concerns over the hepatotoxicity risk of the oral direct thrombin inhibitor ximelagatran swayed a federal advisory panel to recommend against its approval until more data become available.
Effect of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on activated partial thromboplastin time in orthopedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism [Abstract P 3093].
The 18,000-patient Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) study compared the safety and efficacy of two dosages of the direct thrombin inhibitor dabigatran against warfarin in patients with atrial fibrillation (AF) plus at least one additional risk factor for stroke, including prior stroke, low left ventricular ejection fraction, or age 75 or older.